Table 1 Clinicopathologic features of cohort according to PAX8 positivity.

From: PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates

 

All cases

PAX8 (+ve)

PAX8 (−ve)

n

26

14

12

Age

   

  Mean (years)

67

67

66

Sex

   

  M

21 (81%)

13 (93%)

8 (67%)

  F

5 (19%)

1 (7%)

4 (33%)

Procedure

   

  TURBT

12 (46%)

7 (50%)

5 (42%)

  Resection

13 (50%)

6 (43%)

7 (58%)

  Cutaneous excision

1 (3.8%)

1 (7%)

0

T-stage

   

  TURBT:

   

  “at least pT1”

4 (15%)

1 (7%)

3 (25%)

  “at least pT2”

8 (31%)

6 (43%)

2 (17%)

  Resections:

   

  pT1

1 (4%)

1 (7%)

0

  pT2a

2 (8%)

1 (7%)

1 (8%)

  pT2b

2 (8%)

2 (14%)

0

  pT3a

3 (12%)

2 (14%)

1 (8%)

  pT3b

2 (8%)

0

2 (17%)

  pT4a

3 (12%)

0

3 (25%)

N stage

   

  Not assessed

13 (50%)

5 (36%)

8 (67%)

  N0

7 (27%)

2 (14%)

5 (42%)

  N1

1 (4%)

1 (7%)

0

  N2

4 (15%)

1 (7%)

3 (25%)

  N3

1 (4%)

0

1 (8%)

Purity of nested features

   

  Pure

14 (54%)

8 (57%)

6 (50%)

  Extensive

5 (19%)

2 (14%)

3 (25%)

  Focal

7 (27%)

4 (29%)

3 (25%)

TERT promoter mutation status

   

  WT

3 (12%)

1 (7%)

2 (17%)

  124C>T

11 (42%)

6 (43%)

5 (42%)

  146C>T

4 (15%)

2 (14%)

2 (17%)

  Inadequate sample

3 (12%)

1 (7%)

2 (17%)

  Not performed

5 (19%)

4 (29%)

1 (8%)